Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

28 Jul 2026, 22:51 UTC · 1h ago

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Gilead Sciences' upcoming quarterly EPS is projected at -$7.09, representing a 452.74% drop compared to the same quarter last year. — A massive projected collapse in quarterly earnings per share typically triggers significant negative price pressure.
-0.80
2
Gilead Sciences is projected to report full-year earnings of -$0.77 per share, a decline of 109.45% from the previous year. — Projected full-year losses after a year of profitability indicate a severe deterioration in the company's fundamental performance.
-0.60
3
The Zacks Consensus Estimate for Gilead Sciences' upcoming quarterly revenue is $7.37 billion, an increase of 4.02% year-over-year. — Modest revenue growth provides a slight offset to earnings declines, suggesting the business is still expanding its top line.
+0.20
4